{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T23:16:52Z","timestamp":1767136612900,"version":"build-2238731810"},"reference-count":18,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T00:00:00Z","timestamp":1596758400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Grant-in-Aid for Scientific Research","award":["19K08082"],"award-info":[{"award-number":["19K08082"]}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Neuropsychopharm Rep"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Considering that the efficacy results of the Japan lurasidone phase 3 trials for acute schizophrenia were inconsistent, we conducted a systematic review and a random\u2010effect model network meta\u2010analysis of those trials to examine whether lurasidone was beneficial for the treatment of Japanese patients with acute schizophrenia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study included the double\u2010blind, randomized trial in Japan that included patients with acute schizophrenia. Efficacy outcomes were improvement of the Positive and Negative Syndrome Scale total score (PANSS\u2010T, primary), positive (PANSS\u2010P), negative (PANSS\u2010N), and general (PANSS\u2010G) subscale scores; and Clinical Global Impression\u2010Severity Scale (CGI\u2010S) score and response rate. Other outcomes were discontinuation rates and incidence of individual adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included four studies (n\u00a0=\u00a01,608). Although both lurasidone 40\u00a0mg\/d (LUR40) and 80\u00a0mg\/d (LUR80) outperformed placebo in PANSS\u2010T [standardized mean difference (95% credible interval): LUR40\u00a0=\u00a0\u22120.298 (\u22120.420, \u22120.176), LUR80\u00a0=\u00a0\u22120.170 (\u22120.320, \u22120.019)], PANSS\u2010P, and CGI\u2010S scores, LUR40 but not LUR80 outperformed placebo in PANSS\u2010N and PANSS\u2010G scores and response rate. LUR40 outperformed LUR80 regarding PANSS\u2010G score. Both LUR40 and LUR80 were associated with a higher incidence of akathisia, somnolence, and increased body weight compared with placebo. Compared with placebo, LUR40 was associated with a higher incidence of weight gain (\u22657%), and LUR80 was associated with a higher incidence of dystonia and weight loss (\u22657%) and higher Drug\u2010Induced Extrapyramidal Symptoms Scale score.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Both LUR40 and LUR80 improved overall symptoms in Japanese patients with acute schizophrenia. However, LUR80 seemed to have a risk of extrapyramidal symptoms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/npr2.12131","type":"journal-article","created":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T19:52:40Z","timestamp":1596829960000},"page":"314-322","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy, tolerability, and safety of lurasidone for acute schizophrenia: A systematic review and network meta\u2010analysis of phase 3 trials in Japan"],"prefix":"10.1002","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9237-2236","authenticated-orcid":false,"given":"Taro","family":"Kishi","sequence":"first","affiliation":[{"name":"Department of Psychiatry Fujita Health University School of Medicine Toyoake Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Nosaka","sequence":"additional","affiliation":[{"name":"Medical Affairs Sumitomo Dainippon Pharma Co., Ltd. Chuo\u2010ku Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Sakuma","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Fujita Health University School of Medicine Toyoake Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Okuya","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Fujita Health University School of Medicine Toyoake Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nakao","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Fujita Health University School of Medicine Toyoake Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,8,7]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/appy.12352"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/appy.12354"},{"key":"e_1_2_9_4_1","article-title":"A 6\u2010Week, Randomized, Double\u2010Blind, Placebo\u2010Controlled Study to Evaluate the Efficacy and Safety of Lurasidone (SM\u201013496) in Acutely Psychotic Subjects with Schizophrenia","author":"P3\u2010J066","year":"2020","journal-title":"EudraCT"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535"},{"key":"e_1_2_9_7_1","unstructured":"ClinicalTrials.gov.http:\/\/clinicaltrialsgov\/"},{"issue":"1","key":"e_1_2_9_8_1","first-page":"94","article-title":"A three arm dose finding study of lurasidone in Japan: Efficacy and tolerability data","volume":"13","author":"P2\u2010J001","year":"2010","journal-title":"International Journal of Neuropsychopharmacology Conference: 27th CINP Congress Hong Kong Conference Publication: (varpagings)"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2008.01808.x"},{"key":"e_1_2_9_10_1","unstructured":"HigginsJ ThomasJ ChandlerJ CumpstonM LiT PageM WelchV.Cochrane handbook for systematic reviews of Interventions version 6.0.www.trainingcochrane.org\/handbook;2019."},{"key":"e_1_2_9_11_1","volume-title":"Manual for the ECDEU assessment battery","author":"Guy W","year":"1970"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"e_1_2_9_13_1","unstructured":"R\u00fcckerG SchwarzerG KrahnU K\u00f6nigJ netmeta: Network Meta\u2010Analysis using Frequentist Methods (R package version 0.9\u20105).https:\/\/CRANR\u2010projectorg\/package=netmeta2017;(accessed March 14 2020)."},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1193"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0099682"},{"key":"e_1_2_9_16_1","volume-title":"Comprehensive Meta\u2010Analysis Software Version 3"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1055\/a-1096-1266"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.19010034"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(19)30416-X"}],"updated-by":[{"DOI":"10.1002\/npr2.12270","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000}}],"container-title":["Neuropsychopharmacology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fnpr2.12131","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/npr2.12131","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/npr2.12131","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/npr2.12131","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T04:52:11Z","timestamp":1693975931000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/npr2.12131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,7]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1002\/npr2.12131"],"URL":"https:\/\/doi.org\/10.1002\/npr2.12131","archive":["Portico"],"relation":{},"ISSN":["2574-173X","2574-173X"],"issn-type":[{"value":"2574-173X","type":"print"},{"value":"2574-173X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,7]]},"assertion":[{"value":"2020-07-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}